search

Active clinical trials for "Hematologic Neoplasms"

Results 1051-1060 of 1132

Immunological Parameters, Neurocognitive Changes, Activity, & Driving Fitness in Patients Undergoing...

Hematologic Neoplasms

Chimeric antigen receptor (CAR) T-cell therapy is a promising new treatment that re-programs patient immune cells to target and destroy cancer cells. Importantly, CAR T-cell therapy has improved overall response rate and durability in patients with refractory or relapsed diffuse large B-cell lymphoma (DLCBL) and acute lymphoblastic leukemia (ALL). Toxicities following CAR T-cell therapy remain a major limitation to expanding access to this promising cancer treatment. Biological predictors of CAR-T-related toxicities are currently lacking, and it remains unknown whether CAR-T-related toxicities lead to subsequent impairments in instrumental activities of daily living. The overarching goal of this project aims to link biological predictors of CAR-T-related toxicities to instrumental activities of daily living, such as physical activity and driving performance. The current study proposes to test the hypothesis that CAR T-cell therapy causes changes in immunological and neurological markers that predict changes in physical activity levels and driving performance.

Withdrawn8 enrollment criteria

Treg Cells for AGVHD in Non-myeloablative UCB Transplant

Hematologic Malignancies

This is a Simon's optimal two-stage phase II trial designed to estimate grade II-IV acute graft-versus-host disease (GVHD) after infusion of T regulatory (nTreg) in a fixed dose ratio to the combined CD3+ cell count of the two graft units in recipients of double UCB transplantation. The nTreg cells (manufactured from a 3rd cord blood unit) are infused on day 0 at least 1 hour after the 2nd unit of the double umbilical cord blood (UCB) transplant. The nTreg cells require an 18 day (±2 days) lead time based on the planned transplant day. The combined CD3+ cell content from the two graft UCB units is enumerated upon thaw (day 0). The patient then receives the number of nTregs cells from the 3rd cord product to achieve a Treg:CD3+ cells ratio of 5:1. The nTreg cell dose depends on the CD3+ cell content of the two graft UCB graft units, but it will not exceed the highest dose level safely tested in the ongoing University of Minnesota phase I Treg dose escalation study MT 2006-01.

Withdrawn38 enrollment criteria

Feasibility and Safety of Functional Performance Testing in Patients Undergoing Hematopoietic Cell...

Acute Myeloid LeukemiaMyelodysplastic Syndrome4 more

The purpose of this study is to see if exercise fitness testing is feasible and safe in persons over 21 years of age who have been diagnosed with a hematological malignancy and are scheduled to undergo a hematopoietic stem cell transplant (HCT). Assessments in this study will look at the capacity of the body before transplantation to see if these measures can help predict how patients do after transplant.

Completed26 enrollment criteria

Characterization of Methylation Patterns in Cancer and Non-Cancer cfDNA

CancerSolid Tumor1 more

Nucleix EpiCheck® tests analyzes the methylation pattern in a panel of DNA methylation biomarkers and determines whether this pattern is consistent with cancer under test or with non-cancer tissue. This study is being performed as part of the development process of the Pan Cancer EpiCheck test which includes the identification of different methylation profiles in various cancer types and healthy controls.

Completed22 enrollment criteria

UF-BMT-HSCT-001: A Non-Interventional Study Evaluating Diet in HSCT Survivors

Hematopoietic Neoplasm

This is a single center, cross-sectional, non-interventional study aimed at the nutritional intake of long-term health of allogeneic or autologous hematopoietic stem cell transplant (HSCT) survivors.

Completed6 enrollment criteria

Comprehensive Study of Social Representation of Platelet Transfusion in Patients Followed for Advanced...

Platelet TransfusionHematological Malignancy1 more

Limited data is available for end of life care in hematologic malignancies, moreover with thrombocytopenic patients. Thrombopenia is a frequent complication, specific of bone marrow involvement in those diseases or its treatments. Yet, a few studies was interested in, whereas platelet transfusion is the only treatment indicated. As it represent a scarce, limited resource, the ethical principles are in conflict in this setting and there's a lack of recommendation. The final decision is take by the clinician and his patient, but no study exist in representation of the two parts. We provide a qualitative study to understand what this decision is made of.

Completed10 enrollment criteria

Nutrition and Outcomes of Hematopoietic Cell Transplantation (HCT)

Allogeneic Stem Cell TransplantGraft Versus Host Disease2 more

Retrospective case-note review to determine if nutrition via the enteral compared to the parenteral route results in better outcomes after haematopoietic cell transplantation.

Completed5 enrollment criteria

Project Affinity: Excess Cancer Blood Testing

Cancer

Study investigating cancer blood samples on an iterative measurement systme

Completed3 enrollment criteria

Effect of Body Mass on Filgrastim Pharmacokinetics

Hematological MalignancyNeutropenia

Studies have shown that different percentages of body fat can alter the way drugs are distributed in the body. This study will use blood samples taken at different time points for patients taking Neupogen to determine if higher body weights affect drug exposure. The information gathered from this study will help understand if patients with higher body weights need a different dosing plan. Patients in this study will have blood draws once before they take Neupogen and 6 times after they take the Neuopen (for a total of 24 hours). These patients will be in the hospital already and will not need to make additional trips back to have blood drawn. A total of about 5-6 tablespoons of blood will be drawn for this study. 15 obese patients and 15 matched, non-obese patients will be enrolled into this study.

Completed12 enrollment criteria

Scripps Tumorgraft Study

Solid Tumor Malignancy or Hematologic Malignancy

Study the genetic traits of cancerous tissues and to help improve cancer treatment by developing tumor models for studying new cancer drugs.

Completed5 enrollment criteria
1...105106107...114

Need Help? Contact our team!


We'll reach out to this number within 24 hrs